Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy.
STAT (signal transducer and activator of transcription)
cancer associated fibroblasts (CAF)
cytokines
tumor development
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2021
accepted:
26
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
2
2022
Statut:
epublish
Résumé
The tumor microenvironment (TME) is composed of a heterogenous population of cells that exist alongside the extracellular matrix and soluble components. These components can shape an environment that is conducive to tumor growth and metastatic spread. It is well-established that stromal cancer-associated fibroblasts (CAFs) in the TME play a pivotal role in creating and maintaining a growth-permissive environment for tumor cells. A growing body of work has uncovered that tumor cells recruit and educate CAFs to remodel the TME, however, the mechanisms by which this occurs remain incompletely understood. Recent studies suggest that the signal transducer and activator of transcription 3 (STAT3) is a key transcription factor that regulates the function of CAFs, and their crosstalk with tumor and immune cells within the TME. CAF-intrinsic STAT3 activity within the TME correlates with tumor progression, immune suppression and eventually the establishment of metastases. In this review, we will focus on the roles of STAT3 in regulating CAF function and their crosstalk with other cells constituting the TME and discuss the utility of targeting STAT3 within the TME for therapeutic benefit.
Identifiants
pubmed: 34858425
doi: 10.3389/fimmu.2021.767939
pmc: PMC8632218
doi:
Substances chimiques
STAT3 Transcription Factor
0
STAT3 protein, human
0
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
767939Informations de copyright
Copyright © 2021 Allam, Yakou, Pang, Ernst and Huynh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Cancer. 2008 Sep;8(9):705-13
pubmed: 19143055
Med Res Rev. 2018 Jul;38(4):1235-1254
pubmed: 28926101
Prostate. 2014 May;74(5):528-36
pubmed: 24435707
Leukemia. 2016 Mar;30(3):640-8
pubmed: 26487273
Oncol Lett. 2017 Feb;13(2):770-776
pubmed: 28356957
Gastroenterology. 2016 Jun;150(7):1545-1557.e2
pubmed: 27072672
Mol Cancer. 2016 Jan 20;15:7
pubmed: 26790618
Sci Transl Med. 2019 Sep 25;11(511):
pubmed: 31554736
J Cell Mol Med. 2020 Jan;24(1):13-24
pubmed: 31642585
Int J Cancer. 2020 Feb 15;146(4):895-905
pubmed: 30734283
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Nat Commun. 2015 Dec 15;6:10204
pubmed: 26667266
Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
Front Oncol. 2021 Jul 14;11:668349
pubmed: 34336660
Oncoimmunology. 2013 Sep 1;2(9):e25563
pubmed: 24319632
Cell. 1995 Jul 28;82(2):241-50
pubmed: 7543024
Nature. 2016 Aug 25;536(7617):479-83
pubmed: 27509858
PLoS One. 2013 Oct 04;8(10):e76373
pubmed: 24124550
Am J Pathol. 2000 Oct;157(4):1137-46
pubmed: 11021818
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Front Immunol. 2018 Jan 31;9:151
pubmed: 29445380
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
EBioMedicine. 2018 Oct;36:209-220
pubmed: 30243489
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Cancer Res. 2014 Jan 1;74(1):374-86
pubmed: 24197137
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
Cancer Res. 2017 Dec 1;77(23):6679-6691
pubmed: 28972076
Immunotherapy. 2012 Nov;4(11):1129-38
pubmed: 23194363
Curr Opin Cell Biol. 2017 Oct;48:87-96
pubmed: 28715714
Biomed Res Int. 2018 Jun 5;2018:6075403
pubmed: 29967776
Mol Cell Biol. 2008 Aug;28(15):4805-18
pubmed: 18519587
Hum Mol Genet. 2006 Aug 15;15(16):2421-37
pubmed: 16835260
Curr Res Transl Med. 2016 Oct - Dec;64(4):171-177
pubmed: 27939455
Science. 1994 Apr 1;264(5155):95-8
pubmed: 8140422
Nat Med. 2002 Oct;8(10):1089-97
pubmed: 12219085
Oncol Rep. 2018 May;39(5):2081-2090
pubmed: 29565447
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
Nature. 2017 Dec 7;552(7683):110-115
pubmed: 29160304
Adv Med Sci. 2015 Sep;60(2):264-72
pubmed: 26057860
J Hepatol. 2020 Nov;73(5):1118-1130
pubmed: 32505533
Front Oncol. 2018 Mar 12;8:49
pubmed: 29594035
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Cancer Treat Res. 2014;159:401-26
pubmed: 24114493
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Nat Rev Immunol. 2019 Feb;19(2):89-103
pubmed: 30464294
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Mol Biol Cell. 2018 Jan 15;29(2):84-95
pubmed: 29142074
Mol Cell Biol. 1993 Jan;13(1):276-88
pubmed: 7678052
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Int J Oncol. 2009 May;34(5):1209-20
pubmed: 19360334
Cell Death Dis. 2019 Mar 20;10(4):273
pubmed: 30894509
Gut. 2017 Jan;66(1):124-136
pubmed: 27402485
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
Nat Struct Mol Biol. 2013 Apr;20(4):469-76
pubmed: 23454976
Gastroenterology. 2011 Oct;141(4):1486-97, 1497.e1-14
pubmed: 21704588
BMC Cancer. 2011 Jun 13;11:245
pubmed: 21668992
Oncogene. 2012 Jan 26;31(4):480-93
pubmed: 21706048
J Tissue Viability. 2011 Nov;20(4):108-20
pubmed: 19995679
Cells. 2021 Feb 02;10(2):
pubmed: 33540679
Semin Immunol. 2020 Apr;48:101417
pubmed: 33077325
Hypertension. 2013 Feb;61(2):437-42
pubmed: 23266544
Nat Commun. 2013;4:2516
pubmed: 24084631
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207781
Trends Cancer. 2019 Apr;5(4):197-199
pubmed: 30961827
Gene. 2003 Mar 13;306:1-12
pubmed: 12657462
Sci Rep. 2019 Feb 28;9(1):3172
pubmed: 30816272
J Radiat Res. 2018 Mar 1;59(2):129-140
pubmed: 29385614
Yonsei Med J. 2017 May;58(3):489-496
pubmed: 28332352
Biochem Biophys Res Commun. 2012 Jun 22;423(1):60-6
pubmed: 22634002
Oncogene. 2017 Feb 23;36(8):1090-1101
pubmed: 27593937
Biochem Soc Trans. 2017 Feb 8;45(1):229-236
pubmed: 28202677
Med Oncol. 2013;30(3):663
pubmed: 23873014
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cancer Res. 2012 Oct 1;72(19):5130-40
pubmed: 22850421
Nat Commun. 2017 Oct 24;8(1):1130
pubmed: 29066712
Sci Rep. 2020 Oct 15;10(1):17444
pubmed: 33060625
Oncotarget. 2016 Mar 22;7(12):13464-78
pubmed: 26859576
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
J Allergy Clin Immunol. 2003 Apr;111(4):875-81
pubmed: 12704372
Cells Tissues Organs. 2008;187(3):165-76
pubmed: 18042973
Cell Commun Signal. 2018 May 18;16(1):21
pubmed: 29776413
Biochem Biophys Res Commun. 2012 Jun 22;423(1):158-63
pubmed: 22634307
Cancer Res. 2013 May 15;73(10):3007-18
pubmed: 23514705
BMC Cancer. 2018 Mar 27;18(1):335
pubmed: 29587663
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Mol Cancer. 2020 Sep 24;19(1):145
pubmed: 32972405
Biochem J. 2006 Jun 1;396(2):307-16
pubmed: 16492137
Molecules. 2020 Oct 20;25(20):
pubmed: 33092283
Stem Cells. 2016 May;34(5):1188-97
pubmed: 26866938
Cancer Cell. 2017 Nov 13;32(5):654-668.e5
pubmed: 29136508
Gut. 2020 Jul;69(7):1269-1282
pubmed: 31685519
Curr Top Microbiol Immunol. 2017;410:47-71
pubmed: 28900681
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
BioDrugs. 2005;19(6):347-54
pubmed: 16392887
Ann Transl Med. 2020 Jul;8(14):877
pubmed: 32793721
FASEB J. 2020 Sep;34(9):11802-11815
pubmed: 32656894
Clin Cancer Res. 2020 Nov 15;26(22):5887-5894
pubmed: 32694160
Sci Transl Med. 2017 Apr 5;9(384):
pubmed: 28381539
Oncol Rep. 2016 Jul;36(1):108-16
pubmed: 27220595
Front Oncol. 2020 Sep 09;10:543562
pubmed: 33014879
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Adv Drug Deliv Rev. 2007 Nov 10;59(13):1293-8
pubmed: 17825946
Cancers (Basel). 2019 Oct 01;11(10):
pubmed: 31581535
Cell. 2014 Sep 25;159(1):80-93
pubmed: 25259922
Oncotarget. 2016 Jan 12;7(2):1168-84
pubmed: 26700461
Oncotarget. 2017 Jun 28;8(44):76116-76128
pubmed: 29100297
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
Elife. 2020 Dec 28;9:
pubmed: 33370234
Cell Cycle. 2010 Sep 1;9(17):3515-33
pubmed: 20855962
Cardiovasc Res. 2014 May 1;102(2):258-69
pubmed: 24728497
Cancer Lett. 2019 Aug 28;458:123-135
pubmed: 31121212
Nanomedicine (Lond). 2016 Oct;11(20):2735-2751
pubmed: 27658725
Cancer Cell. 2011 Aug 16;20(2):229-45
pubmed: 21840487
Science. 2009 Jun 26;324(5935):1713-6
pubmed: 19556508
Front Oncol. 2020 May 05;10:652
pubmed: 32432040
Cancers (Basel). 2021 Mar 10;13(6):
pubmed: 33801815
Cell Death Dis. 2018 Mar 19;9(4):422
pubmed: 29556041
J Immunol. 2015 Apr 1;194(7):3422-31
pubmed: 25740948
Theranostics. 2017 Sep 15;7(16):3972-3988
pubmed: 29109792
Gastroenterology. 2007 Nov;133(5):1637-48
pubmed: 17983808
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4
pubmed: 9108058
Sci Rep. 2017 Oct 3;7(1):12574
pubmed: 28974764
J Immunol Res. 2021 Jul 13;2021:8840066
pubmed: 34337083
Clin Cancer Res. 2018 Nov 1;24(21):5407-5421
pubmed: 29959142
Cancer Immunol Res. 2014 Mar;2(3):187-93
pubmed: 24778314
Biomedicines. 2021 Feb 12;9(2):
pubmed: 33673239
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6180-5
pubmed: 11353845
J Wound Care. 2013 Aug;22(8):407-8, 410-12
pubmed: 23924840
Cancer Gene Ther. 2021 Sep;28(9):984-999
pubmed: 33712707
Oncogene. 2015 Oct 8;34(41):5252-63
pubmed: 25619838